Pomanda estimates the enterprise value of CANCER FOCUS NORTHERN IRELAND at £2.5m based on a Turnover of £4.8m and 0.52x industry multiple (adjusted for size and gross margin).
cancer focus northern irelandEstimated Valuation
£870.4k
Pomanda estimates the enterprise value of CANCER FOCUS NORTHERN IRELAND at £870.4k based on an EBITDA of £220.5k and a 3.95x industry multiple (adjusted for size and gross margin).
cancer focus northern irelandEstimated Valuation
£7.4m
Pomanda estimates the enterprise value of CANCER FOCUS NORTHERN IRELAND at £7.4m based on Net Assets of £3.3m and 2.23x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Cancer Focus Northern IrelandOverview
Cancer Focus Northern Ireland is a live company located in co antrim, BT9 6DX with a Companies House number of NI049781. It operates in the other human health activities sector, SIC Code 86900. Founded in February 2004, it's largest shareholder is
unknown.
Cancer Focus Northern Ireland is a mature,
small sized company, Pomanda has estimated its turnover at
£4.8m with
healthy
growth in recent years.
Pomanda's financial health check has awarded Cancer Focus Northern Ireland a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs
Health Rating5out of 5
5 Strong
4 Regular
2 Weak
Size
annual sales of £4.8m, make it larger than the average company (£731.1k)
£4.8m - Cancer Focus Northern Ireland
£731.1k - Industry AVG
Growth
3 year (CAGR) sales growth of 8%, show it is growing at a similar rate (7.2%)
8% - Cancer Focus Northern Ireland
7.2% - Industry AVG
Production
with a gross margin of 38.4%, this company has a comparable cost of product (38.4%)
38.4% - Cancer Focus Northern Ireland
38.4% - Industry AVG
Profitability
an operating margin of 3.3% make it less profitable than the average company (5.2%)
3.3% - Cancer Focus Northern Ireland
5.2% - Industry AVG
Employees
with 115 employees, this is above the industry average (18)
115 - Cancer Focus Northern Ireland
18 - Industry AVG
Pay Structure
on an average salary of £23.2k, the company has an equivalent pay structure (£26.5k)
£23.2k - Cancer Focus Northern Ireland
£26.5k - Industry AVG
Efficiency
resulting in sales per employee of £41.4k, this is equally as efficient (£45.8k)
£41.4k - Cancer Focus Northern Ireland
£45.8k - Industry AVG
Debtor Days
it gets paid by customers after 1 days, this is earlier than average (20 days)
1 days - Cancer Focus Northern Ireland
20 days - Industry AVG
Creditor Days
its suppliers are paid after 9 days, this is quicker than average (18 days)
9 days - Cancer Focus Northern Ireland
18 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Cancer Focus Northern Ireland
- - Industry AVG
Cash Balance
has cash to cover current liabilities
for 289 weeks, this is more cash available to meet short term requirements (124 weeks)
289 weeks - Cancer Focus Northern Ireland
124 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 5.4%, this is a lower level of debt than the average (22.7%)
5.4% - Cancer Focus Northern Ireland
22.7% - Industry AVG
CANCER FOCUS NORTHERN IRELAND financials
EXPORT
Cancer Focus Northern Ireland's latest turnover from March 2024 is £4.8 million and the company has net assets of £3.3 million. According to their latest financial statements, Cancer Focus Northern Ireland has 115 employees and maintains cash reserves of £1.1 million as reported in the balance sheet.
Data source:Companies House, Pomanda Estimates
Mar 2024
Mar 2023
Mar 2022
Jul 2021
Jul 2020
Jul 2019
Jul 2018
Jul 2017
Jul 2016
Jul 2015
Jul 2014
Jul 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Turnover
4,761,619
4,063,473
2,569,506
3,770,262
3,714,479
4,228,532
3,582,416
3,263,165
3,612,975
3,970,632
3,674,175
4,229,697
3,324,631
3,178,710
3,113,208
2,859,188
Other Income Or Grants
Cost Of Sales
2,932,280
2,532,086
1,634,580
2,499,060
2,354,808
2,705,105
2,302,446
1,983,193
2,234,535
2,493,001
2,289,734
2,583,677
1,935,586
1,824,937
1,738,759
Gross Profit
1,829,339
1,531,387
934,926
1,271,202
1,359,671
1,523,427
1,279,970
1,279,972
1,378,440
1,477,631
1,384,441
1,646,020
1,389,045
1,353,773
1,374,449
Admin Expenses
1,670,751
1,493,986
568,882
1,000,889
1,551,551
1,212,392
1,153,049
1,521,057
1,607,032
1,600,810
1,707,490
1,217,325
1,711,730
1,449,689
1,583,468
542,828
Operating Profit
158,588
37,401
366,044
270,313
-191,880
311,035
126,921
-241,085
-228,592
-123,179
-323,049
428,695
-322,685
-95,916
-209,019
-542,828
Interest Payable
10,851
11,252
11,541
9,321
5,808
5,223
4,880
5,124
4,668
2,819
Interest Receivable
Pre-Tax Profit
160,855
64,568
294,544
209,964
-197,519
255,220
104,711
-240,218
-226,084
-119,944
-319,129
333,909
-317,288
-89,993
-202,819
-539,640
Tax
Profit After Tax
160,855
64,568
294,544
209,964
-197,519
255,220
104,711
-240,218
-226,084
-119,944
-319,129
333,909
-317,288
-89,993
-202,819
-539,640
Dividends Paid
Retained Profit
160,855
64,568
294,544
209,964
-197,519
255,220
104,711
-240,218
-226,084
-119,944
-319,129
333,909
-317,288
-89,993
-202,819
-539,640
Employee Costs
2,664,235
2,270,321
1,350,810
2,541,142
2,483,325
2,376,217
2,157,672
2,222,235
2,368,130
2,328,545
2,390,064
2,140,120
1,927,789
1,748,711
1,726,546
1,713,378
Number Of Employees
115
99
93
118
118
125
112
108
116
119
121
119
122
111
95
93
EBITDA*
220,508
115,788
431,703
371,743
-92,588
411,333
240,089
-128,464
-118,363
-16,506
-227,678
491,575
-263,622
-8,941
-103,385
-437,529
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2024
Mar 2023
Mar 2022
Jul 2021
Jul 2020
Jul 2019
Jul 2018
Jul 2017
Jul 2016
Jul 2015
Jul 2014
Jul 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Tangible Assets
214,152
144,774
1,431,823
1,455,892
1,524,305
1,605,587
1,633,203
1,684,878
1,770,945
1,874,993
1,854,930
1,840,581
1,684,040
1,670,765
1,705,209
1,870,732
Intangible Assets
Investments & Other
831,232
734,796
752,222
739,691
656,794
784,837
585,313
575,348
756,503
611,169
631,078
546,064
470,565
471,941
430,205
405,895
Debtors (Due After 1 year)
Total Fixed Assets
1,045,384
879,570
2,184,045
2,195,583
2,181,099
2,390,424
2,218,516
2,260,226
2,527,448
2,486,162
2,486,008
2,386,645
2,154,605
2,142,706
2,135,414
2,276,627
Stock & work in progress
36,467
Trade Debtors
23,849
81,563
21,164
8,487
16,198
16,079
36,370
12,442
168,091
35,805
40,886
76,966
56,220
19,084
21,196
12,635
Group Debtors
Misc Debtors
394,002
119,368
104,549
152,315
110,092
123,151
71,414
99,576
82,727
120,743
208,533
253,382
38,164
212,435
31,541
133,632
Cash
1,057,037
1,345,054
1,345,209
1,178,828
928,670
542,938
537,500
403,134
290,515
712,845
581,000
986,867
994,276
1,164,446
1,204,781
1,275,344
misc current assets
995,000
1,179,796
total current assets
2,469,888
2,725,781
1,470,922
1,339,630
1,054,960
682,168
645,284
515,152
541,333
869,393
830,419
1,317,215
1,088,660
1,395,965
1,257,518
1,458,078
total assets
3,515,272
3,605,351
3,654,967
3,535,213
3,236,059
3,072,592
2,863,800
2,775,378
3,068,781
3,355,555
3,316,427
3,703,860
3,243,265
3,538,671
3,392,932
3,734,705
Bank overdraft
41,032
29,394
29,796
29,796
Bank loan
Trade Creditors
72,377
66,280
56,720
90,121
44,713
25,529
74,830
91,775
127,856
75,504
71,684
166,373
126,450
133,980
30,434
29,740
Group/Directors Accounts
other short term finances
hp & lease commitments
3,436
4,123
4,123
4,123
470
8,375
5,122
other current liabilities
117,216
161,632
250,419
364,790
301,439
168,638
165,765
154,825
225,028
351,153
199,306
190,483
198,471
169,155
70,635
229,672
total current liabilities
189,593
268,944
336,533
484,707
375,948
194,167
240,595
246,600
356,320
430,780
275,113
360,979
324,921
303,605
109,444
264,534
loans
86,424
133,019
159,635
179,204
hp & lease commitments
3,436
7,559
11,682
483
11,050
Accruals and Deferred Income
other liabilities
provisions
total long term liabilities
86,424
133,019
159,635
179,204
3,436
7,559
11,682
483
11,050
total liabilities
189,593
355,368
469,552
644,342
555,152
194,167
240,595
246,600
356,320
434,216
282,672
372,661
324,921
303,605
109,927
275,584
net assets
3,325,679
3,249,983
3,185,415
2,890,871
2,680,907
2,878,425
2,623,205
2,528,778
2,712,461
2,921,339
3,033,755
3,331,199
2,918,344
3,235,066
3,283,005
3,459,121
total shareholders funds
3,325,679
3,249,983
3,185,415
2,890,871
2,680,907
2,878,425
2,623,205
2,528,778
2,712,461
2,921,339
3,033,755
3,331,199
2,918,344
3,235,066
3,283,005
3,459,121
Mar 2024
Mar 2023
Mar 2022
Jul 2021
Jul 2020
Jul 2019
Jul 2018
Jul 2017
Jul 2016
Jul 2015
Jul 2014
Jul 2013
Jul 2012
Jul 2011
Jul 2010
Jul 2009
Operating Activities
Operating Profit
158,588
37,401
366,044
270,313
-191,880
311,035
126,921
-241,085
-228,592
-123,179
-323,049
428,695
-322,685
-95,916
-209,019
-542,828
Depreciation
61,920
78,387
65,659
101,430
99,292
100,298
113,168
112,621
110,229
106,673
95,371
62,880
59,063
86,975
105,634
105,299
Amortisation
Tax
Stock
-36,467
36,467
Debtors
216,920
75,218
-35,089
34,512
-12,940
31,446
-4,234
-138,800
94,270
-92,871
-80,929
235,964
-137,135
178,782
-93,530
146,267
Creditors
6,097
9,560
-33,401
45,408
19,184
-49,301
-16,945
-36,081
52,352
3,820
-94,689
39,923
-7,530
103,546
694
29,740
Accruals and Deferred Income
-44,416
-88,787
-114,371
63,351
132,801
2,873
10,940
-70,203
-126,125
151,847
8,823
-7,988
29,316
98,520
-159,037
229,672
Deferred Taxes & Provisions
Cash flow from operations
-34,731
-38,657
319,020
445,990
72,337
333,459
238,318
-95,948
-286,406
232,032
-232,615
287,546
-104,701
14,343
-131,731
-360,851
Investing Activities
capital expenditure
-67,063
211,136
-134,309
-99,299
-173,048
-198,495
-69,926
-52,213
867
-8,078
Change in Investments
96,436
-17,426
12,531
82,897
-128,043
199,524
9,965
-181,155
145,334
-19,909
85,014
75,499
-1,376
41,736
24,310
405,895
cash flow from investments
-96,436
17,426
-12,531
-82,897
128,043
-199,524
-77,028
392,291
-279,643
-79,390
-258,062
-273,994
-68,550
-93,949
-23,443
-413,973
Financing Activities
Bank loans
Group/Directors Accounts
Other Short Term Loans
Long term loans
-86,424
-46,595
-26,616
-19,569
179,204
Hire Purchase and Lease Commitments
-3,436
-4,123
-4,123
-4,123
15,805
-470
-8,388
-7,314
16,172
other long term liabilities
share issue
-85,159
1
-10,284
56,535
17,206
7,528
21,685
78,946
566
42,054
26,703
3,998,761
interest
-10,851
-11,252
-11,541
-9,321
-5,808
-5,223
-4,880
-5,124
-4,668
-2,819
cash flow from financing
-171,583
-46,595
-26,616
-19,569
179,205
-21,135
41,847
1,542
-5,916
11,754
89,528
-4,784
28,542
14,721
4,012,114
cash and cash equivalents
cash
-288,017
-155
166,381
250,158
385,732
5,438
134,366
112,619
-422,330
131,845
-405,867
-7,409
-170,170
-40,335
-70,563
1,275,344
overdraft
-41,032
11,638
-402
29,796
change in cash
-246,985
-11,793
166,783
250,158
355,936
5,438
134,366
112,619
-422,330
131,845
-405,867
-7,409
-170,170
-40,335
-70,563
1,275,344
cancer focus northern ireland Credit Report and Business Information
Very Low Risk70 - 100
Low Risk50 - 70
Moderate Risk30 - 50
High Risk20 - 30
Very High Risk0 - 20
Get a comprehensive credit check for cancer focus northern ireland. Get real-time insights into cancer focus northern ireland's credit score, group structure and payment trends.
Perform a competitor analysis for cancer focus northern ireland by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in BT9 area or any other competitors across 12 key performance metrics.
cancer focus northern ireland Ownership
CANCER FOCUS NORTHERN IRELAND group structure
Cancer Focus Northern Ireland has 1 subsidiary company.
The sole shareholder of Cancer Focus Northern Ireland is -.
-
-
cancer focus northern ireland directors
Cancer Focus Northern Ireland currently has 12 directors.
The longest serving directors include
Mr John Carson (Dec 2006) and
Professor Mark Lawler (Nov 2015).
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
February 2004
age
21
incorporated
UK
ultimate parent company
None
accounts
Full Accounts
last accounts submitted
March 2024
previous names
ulster cancer foundation - the (May 2012)
accountant
-
auditor
FINEGAN GIBSON LTD
address
40 - 44 eglantine ave,, belfast, co antrim, n. ireland, BT9 6DX
Bank
DANSKE BANK LIMITED
Legal Advisor
EDWARDS
cancer focus northern ireland Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 2 charges/mortgages relating to cancer focus northern ireland. Currently there are 1 open charges and 1 have been satisfied in the past.
cancer focus northern ireland Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for CANCER FOCUS NORTHERN IRELAND. This can take several minutes, an email will notify you when this has completed.
cancer focus northern irelandCompanies House Filings - See Documents
